fludarabine has been researched along with flucytosine in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Chevrier, S; Houot, R; Lamy, T; Marchand, T; Poullot, E; Revest, M; Tattevin, P | 1 |
| Guillen, KP; Harrison, RG; Kurkjian, C; Restuccia, A | 1 |
5 other study(ies) available for fludarabine and flucytosine
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Early cryptococcal meningitis following treatment with rituximab, fludarabine and cyclophosphamide in a patient with chronic lymphocytic leukemia.
Topics: Aged; Amphotericin B; Antibodies, Monoclonal, Murine-Derived; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Cryptococcus neoformans; Cyclophosphamide; Drug Therapy, Combination; Fatal Outcome; Flucytosine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Meningitis, Cryptococcal; Rituximab; Time Factors; Vidarabine | 2013 |
Annexin V-Directed Enzyme Prodrug Therapy Plus Docetaxel for the Targeted Treatment of Pancreatic Cancer.
Topics: Adenine; Adenocarcinoma; Annexin A5; Antineoplastic Combined Chemotherapy Protocols; Carbon-Sulfur Lyases; Cell Death; Cell Line, Tumor; Cytosine Deaminase; Docetaxel; Dose-Response Relationship, Drug; Enzymes; Flucytosine; Fluorouracil; Humans; Methanol; Molecular Targeted Therapy; Organoselenium Compounds; Pancreatic Neoplasms; Prodrugs; Purine-Nucleoside Phosphorylase; Recombinant Fusion Proteins; Selenomethionine; Taxoids; Tubulin Modulators; Vidarabine | 2015 |